Clomid and Twins: The Real Odds, by the Numbers

Clomid and twins is the question behind a surprising share of searches for the drug, some from women who fear a multiple pregnancy and some who want one. The numbers are better documented than for almost any other Clomid question, because the label reports the outcome of 2,369 pregnancies from the original trials and two large randomised trials since have counted twins as a safety outcome. Across those sources the twin rate on Clomid sits between 6% and 7.5% of pregnancies, against a background rate of roughly 1 in 80 for natural conception. That is a real increase, about five-fold, and still means more than nine in ten Clomid pregnancies are singletons.

This page gives the figures from each source, explains why the dose does not change them in the way people assume, what "best days to take Clomid for twins" gets wrong, and why prescribers treat a twin pregnancy as a complication rather than a bonus.

The label states the multiple-pregnancy incidence as 7.98% and asks prescribers to tell patients that the chance of a multiple pregnancy, including tubal and combined tubal-and-uterine pregnancy, is increased, and to explain the complications. The survival figures are the reason: the last two rows of the table are the difference between a singleton and a multiple pregnancy in the trial data.

Two trials in women with polycystic ovary syndrome counted twins against comparators. In the 2014 New England Journal of Medicine trial of 750 women (Legro and colleagues), twin pregnancy occurred in 7.4% of Clomid pregnancies versus 3.4% on letrozole, with live birth higher on letrozole (27.5% vs 19.1%). In the 2007 trial of 626 women by the same group, the multiple-pregnancy rate was 6.0% on Clomid, 0% on metformin alone and 3.1% on the combination. The pattern is consistent: Clomid roughly doubles the twin rate relative to letrozole, and letrozole's lower twin rate is one reason it has displaced Clomid as first line in PCOS, covered in Clomid vs letrozole.

Clomid blocks estrogen receptors in the hypothalamus so the pituitary releases more FSH. In a natural cycle, FSH falls once one follicle takes the lead and the others stop growing; on Clomid the extra FSH keeps more than one follicle growing to maturity, and if two are released and both fertilise, the result is fraternal twins. The 1:5 ratio of identical to fraternal twins in the label is the signature of that mechanism: Clomid makes dizygotic twins by releasing two eggs, and has little effect on the splitting of one embryo that makes identical twins. How many follicles reach maturity depends on the woman's ovarian reserve and sensitivity far more than on the tablet count.

Not in the way the search "Clomid dosage for twins" implies. The label's protocol raises the dose from 50 mg to 100 mg only when the first course produced no ovulation at all, and says not to go beyond 100 mg for five days. A woman who ovulates on 50 mg stays on 50 mg. So the women on 100 mg are, by selection, the ones whose ovaries responded least, not women being pushed toward multiple follicles. There is no dose on the label that is prescribed to produce twins, and taking 100 mg when 50 mg already works adds the dose-related risks the label lists, visual symptoms and ovarian enlargement, without a documented increase in twinning. A prescriber who finds three or more mature follicles on ultrasound before ovulation will usually advise against intercourse that cycle, because the aim is one.

There is no such schedule. The course is five days starting on or about cycle day 5 on the label; some clinics start on day 3, and trials comparing early and late starts have looked at ovulation and pregnancy rates, not twinning. Shifting the start by two days changes when the follicles grow, not how many. Timing intercourse to ovulation, which the label does recommend, improves the chance of any pregnancy and leaves the twin fraction where it was.

Twin pregnancies carry higher rates of preterm birth, low birth weight, pre-eclampsia and caesarean delivery than singletons, and the label's own survival figures, 83% for infants of multiple births against 98% for singletons, are the trial-era version of that. That is why monitoring with ultrasound, dose discipline and the move to letrozole in PCOS all exist: to get one healthy pregnancy. A woman who wants twins is asking a fertility drug to deliver its best-known complication on purpose, and no prescriber will plan a cycle that way. The things to avoid guide covers the other ways a cycle goes wrong.

Clomid.org is an independent educational resource. We are not affiliated with any pharmaceutical manufacturer, compounding pharmacy, telehealth company or healthcare provider. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.